Mizuho Securities Maintains Alector(ALEC.US) With Buy Rating
Mizuho Securities Reaffirms Their Buy Rating on Alector (ALEC)
BofA Securities Maintains Alector(ALEC.US) With Hold Rating, Maintains Target Price $9
Barclays Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $12
Alector (ALEC) Receives a Buy From Barclays
Morgan Stanley Maintains Alector(ALEC.US) With Hold Rating, Maintains Target Price $10
Alector's AL002 Holds Potential Amidst Uncertainties: A Hold Rating Analysis
Alector Analyst Ratings
TD Cowen Maintains Alector(ALEC.US) With Buy Rating
Mizuho Securities Maintains Alector(ALEC.US) With Buy Rating, Maintains Target Price $9
Alector's Strong Outlook: Advancing Pipeline and Undervalued Stock Prompt Buy Rating
Analyst Issues Buy Rating on Alector Amid Promising Biomarker Research and Positive FDA Interactions
TD Cowen Remains a Buy on Alector (ALEC)
Alector Analyst Ratings
Goldman Sachs Maintains Alector(ALEC.US) With Sell Rating
Goldman Sachs Keeps Their Sell Rating on Alector (ALEC)
Alector Analyst Ratings
Barclays Sticks to Their Buy Rating for Alector (ALEC)
Alector Analyst Ratings
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Revance Therapeutics (RVNC) and Alector (ALEC)